Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Harvard Business School
Baxter
Merck
Moodys

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Mirodenafil

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Mirodenafil?

Mirodenafil is an investigational drug.

There have been 4 clinical trials for Mirodenafil. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2011.

The most common disease conditions in clinical trials are Erectile Dysfunction, Urologic Diseases, and Renal Insufficiency. The leading clinical trial sponsors are SK Chemicals Co.,Ltd., Janssen Korea, Ltd., Korea, and Asan Medical Center.

There are twelve US patents protecting this investigational drug and one hundred and fifty-seven international patents.

Recent Clinical Trials for Mirodenafil
TitleSponsorPhase
Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mgSK Chemicals Co.,Ltd.Phase 1
Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 50mgSK Chemicals Co.,Ltd.Phase 1
A Study to Evaluate the Safety and Effectiveness of Mirodenafil in Korean Patients With Erectile DysfunctionJanssen Korea, Ltd., KoreaPhase 4

See all Mirodenafil clinical trials

Clinical Trial Summary for Mirodenafil

Top disease conditions for Mirodenafil
Top clinical trial sponsors for Mirodenafil

See all Mirodenafil clinical trials

US Patents for Mirodenafil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Mirodenafil   Start Trial Treatment of erectile dysfunction and other indications Strategic Science & Technologies, LLC (Cambridge, MA)   Start Trial
Mirodenafil   Start Trial Pyrrolopyrimidinone derivatives, process of preparation and use SK Chemicals Co., Ltd. (Suwon, KR) In2Gen Co., Ltd. (Seoul, KR)   Start Trial
Mirodenafil   Start Trial Composition for reducing skin wrinkles including PDE5 inhibitor SK CHEMICALS CO., LTD. (Seongnam, Gyeonggi-Do, KR)   Start Trial
Mirodenafil   Start Trial Methods and compositions for oral administration of melanocortin receptor agonist compounds   Start Trial
Mirodenafil   Start Trial Treatment of erectile dysfunction and other indications Strategic Science & Technologies, LLC (Cambridge, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Mirodenafil

Drugname Country Document Number Estimated Expiration Related US Patent
Mirodenafil Australia 2009348470 2029-06-24   Start Trial
Mirodenafil Australia 2015203547 2029-06-24   Start Trial
Mirodenafil Australia 2016200596 2029-06-24   Start Trial
Mirodenafil Australia 2017206223 2029-06-24   Start Trial
Mirodenafil Australia 2019200847 2029-06-24   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Johnson and Johnson
AstraZeneca
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.